Interactions between pharmacologic concentrations of plasminogen activators and platelets
- 1 July 1989
- journal article
- research article
- Published by Elsevier in Fibrinolysis
- Vol. 3 (3) , 127-136
- https://doi.org/10.1016/0268-9499(89)90010-6
Abstract
No abstract availableThis publication has 34 references indexed in Scilit:
- Preliminary Report: Findings from the Aspirin Component of the Ongoing Physicians' Health StudyNew England Journal of Medicine, 1988
- A Randomized Trial of Intravenous Tissue Plasminogen Activator for Acute Myocardial Infarction with Subsequent Randomization to Elective Coronary AngioplastyNew England Journal of Medicine, 1987
- A randomized, blinded, placebo-controlled trial of recombinant human tissue-type plasminogen activator in patients with unstable angina pectoris.Circulation, 1987
- Acute coronary reocclusion after thrombolysis with recombinant human tissue-type plasminogen activator: prevention by a maintenance infusion.Circulation, 1986
- Prevention of coronary thrombosis with subthrombolytic doses of tissue-type plasminogen activator.Circulation, 1985
- Role of platelets and thrombosis in coronary atherosclerotic disease and sudden deathJournal of the American College of Cardiology, 1985
- Plasmin inhibition of platelet function and of arachidonic acid metabolism.Journal of Clinical Investigation, 1985
- Scintigraphic detection of coronary artery thrombi in patients with acute myocardial infarctionJournal of the American College of Cardiology, 1984
- Protective Effects of Aspirin against Acute Myocardial Infarction and Death in Men with Unstable AnginaNew England Journal of Medicine, 1983
- Pathology of acute myocardial infarction with particular reference to occlusive coronary thrombi.Heart, 1976